|
Mr. Pritchard joins KaloBios with more than 25 years of experience in general management, business development and financial management within the biopharmaceutical industry. Most recently he held the position of CBO at Rinat Neuroscience Corporation, where he managed the negotiations on the acquisition of Rinat by Pfizer in 2006 for a reported $500 million. Prior to that he was CFO at Matrix Pharmaceuticals, and managed the sale of the company to Chiron Corporation in 2002 (now Novartis). Between 1992 and 2000 David served as VP, Business Development and CFO of Metabolex, Inc. where he completed three rounds of financing and negotiated four worldwide corporate alliances with major pharmaceutical companies, and in-licensed metaglidasen. He started his biotechnology career at Triton Biosciences, Inc. as one of the founding managers, where he held various positions including heading up the sales and marketing efforts, commercial development, a business unit, and ultimately managed the sale of Triton (predominately to Schering AG, now Bayer). Triton developed Betaseron� for multiple sclerosis (2005 sales exceeded $1 billion), and Fludara� for leukemia. David holds an MBA degree from Stanford University, and a BS in Chemical Engineering from Cornell. | 